Revista iberoamericana de micologia · 2009
[Micafungin for the treatment of neonatal invasive candidiasis].
Сравнительное исследованиеСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Infante-López María Elena, Rojo-Conejo Pablo
Аннотация
BACKGROUND: In neonatal intensive care units, deep fungal disease due to Candida spp. are an important clinical problem, partly due to the increasing prevalence of Candida disease and also to the high associated and constant morbimortality; both factors are independently maintained though there has been a significant improvement in the management of neonatal patients.
AIMS: To define the therapeutic use of micafungin for the treatment of neonatal invasive candidiasis.
METHODS: We use a review of biomedic data bases namely Medline and EMBASE.
CONCLUSIONS: Micafungin is the latest introduced echinocandin. It has a wide spectrum of activity and covers Candida albicans and non-albicans Candida species. It has scarce drugs interactions and is devoid of toxicity, being an attractive approach for the treatment of invasive candidiasis (without meningitis, endocarditis and endophthalmitis). Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates.
AIMS: To define the therapeutic use of micafungin for the treatment of neonatal invasive candidiasis.
METHODS: We use a review of biomedic data bases namely Medline and EMBASE.
CONCLUSIONS: Micafungin is the latest introduced echinocandin. It has a wide spectrum of activity and covers Candida albicans and non-albicans Candida species. It has scarce drugs interactions and is devoid of toxicity, being an attractive approach for the treatment of invasive candidiasis (without meningitis, endocarditis and endophthalmitis). Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates.
Предметные рубрики MeSH
AdolescentAdultAge FactorsAmphotericin BAntifungal AgentsCandidiasisChildChild, PreschoolClinical Trials as TopicEchinocandinsFemaleFungemiaHumansInfantInfant, NewbornInfant, PrematureInfant, Premature, DiseasesLipopeptidesMaleMeta-Analysis as TopicMicafunginMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicRetrospective Studies